{
    "id": 24862,
    "fullName": "HGF positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "HGF positive indicates the presence of the HGF gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3082,
        "geneSymbol": "HGF",
        "terms": [
            "HGF",
            "DFNB39",
            "F-TCF",
            "HGFB",
            "HPTA",
            "SF"
        ]
    },
    "variant": "positive",
    "createDate": "07/27/2016",
    "updateDate": "07/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16398,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAIT301 inhibited phosphorylation of Met and downstream targets, and reduced migration and growth of nasopharygeal carcinoma cell lines treated with HGF in culture (PMID: 24722284).",
            "molecularProfile": {
                "id": 25620,
                "profileName": "HGF positive"
            },
            "therapy": {
                "id": 8017,
                "therapyName": "SAIT301",
                "synonyms": null
            },
            "indication": {
                "id": 9261,
                "name": "nasopharynx carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14479,
                    "pubMedId": 24722284,
                    "title": "Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24722284"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18782,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OMO-1 inhibited tumor growth in a cell line xenograft model of HGF autocrine glioblastoma (Cancer Res 2018;78(13 Suppl):Abstract nr 4791).",
            "molecularProfile": {
                "id": 25620,
                "profileName": "HGF positive"
            },
            "therapy": {
                "id": 8846,
                "therapyName": "OMO-1",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16455,
                    "pubMedId": null,
                    "title": "OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models",
                    "url": "https://cancerres.aacrjournals.org/content/78/13_Supplement/4791"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7507,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) and JNJ-61186372 induced tumor regression in HGF-expressing non-small cell lung cancer cell line xenograft models harboring EGFR L858R and EGFR T790M, with increased efficacy compared to either agent alone, and resulted in durable response following cessation of treatment (PMID: 27216193).",
            "molecularProfile": {
                "id": 25622,
                "profileName": "EGFR T790M EGFR L858R HGF pos"
            },
            "therapy": {
                "id": 4502,
                "therapyName": "JNJ-61186372 + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6352,
                    "pubMedId": 27216193,
                    "title": "A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7501,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JNJ-61186372 inhibited MET and EGFR expression and downstream signaling and reduced tumor growth in HGF-expressing non-small cell lung cancer cell line xenograft models harboring EGFR L858R and EGFR T790M (PMID: 27216193).",
            "molecularProfile": {
                "id": 25622,
                "profileName": "EGFR T790M EGFR L858R HGF pos"
            },
            "therapy": {
                "id": 4491,
                "therapyName": "JNJ-61186372",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6352,
                    "pubMedId": 27216193,
                    "title": "A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8710,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited growth of a HGF-driven glioblastoma cell line with wild-type MET in culture and inhibited tumor growth in xenograft models (PMID: 27550450).",
            "molecularProfile": {
                "id": 26414,
                "profileName": "HGF pos MET wild-type"
            },
            "therapy": {
                "id": 4799,
                "therapyName": "KTN0073-IgG2",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6713,
                    "pubMedId": 27550450,
                    "title": "Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9060,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Xalkori (crizotinib) to treatment with WZ4002 delayed the onset of drug resistance in a non-small cell lung cancer cell line harboring EGFR E746_A750del and activation of HGF signaling (PMID: 26036643).",
            "molecularProfile": {
                "id": 26705,
                "profileName": "EGFR E746_A750del HGF pos"
            },
            "therapy": {
                "id": 4872,
                "therapyName": "Crizotinib + WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6890,
                    "pubMedId": 26036643,
                    "title": "Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26036643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10064,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Altiratinib (DCC-701) increased survival in a MET and HGF-expressing glioblastoma cell line xenograft model (PMID: 26285778).",
            "molecularProfile": {
                "id": 27233,
                "profileName": "HGF pos MET pos"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10065,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Altiratinib (DCC-701) and Avastin (bevacizumab) resulted in decreased tumor growth, increased survival, and a decrease in TIE2-expressing circulating monocytes in a MET and HGF-expressing glioblastoma cell line xenograft model (PMID: 26285778).",
            "molecularProfile": {
                "id": 27233,
                "profileName": "HGF pos MET pos"
            },
            "therapy": {
                "id": 4353,
                "therapyName": "Altiratinib + Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10069,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Altiratinib (DCC-2701) to Tafinlar (dabrafenib) therapy resulted in decreased proliferation and ERK activation in a melanoma cell line harboring BRAF V600E with HGF-mediated resistance to Tafinlar (dabrafenib) in culture (PMID: 26285778).",
            "molecularProfile": {
                "id": 27234,
                "profileName": "BRAF V600E HGF pos"
            },
            "therapy": {
                "id": 5361,
                "therapyName": "Altiratinib + Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21045,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in enhanced killing of a colorectal cancer cell line harboring BRAF V600E and expressing HGF in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 27234,
                "profileName": "BRAF V600E HGF pos"
            },
            "therapy": {
                "id": 9541,
                "therapyName": "Capmatinib + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10070,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Altiratinib (DCC-2701) to Mekinist (trametinib) therapy resulted in decreased proliferation of a BRAF-mutant melanoma cell line with HGF-mediated resistance to Mekinist (trametinib) in culture (PMID: 26285778).",
            "molecularProfile": {
                "id": 27235,
                "profileName": "BRAF mut HGF pos"
            },
            "therapy": {
                "id": 5362,
                "therapyName": "Altiratinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25620,
            "profileName": "HGF positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25622,
            "profileName": "EGFR T790M EGFR L858R HGF pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26414,
            "profileName": "HGF pos MET wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26705,
            "profileName": "EGFR E746_A750del HGF pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27233,
            "profileName": "HGF pos MET pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27234,
            "profileName": "BRAF V600E HGF pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27235,
            "profileName": "BRAF mut HGF pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}